AAAAAA

   
Results: 1-15 |
Results: 15
Oral contraceptives and the risk of venous thrombosis.
Authors: Vandenbroucke, JP Rosing, J Bloemenkamp, KWM Middeldorp, S Helmerhorst, FM Bouma, BN Rosendaal, FR
Citation: Jp. Vandenbroucke et al., Oral contraceptives and the risk of venous thrombosis., N ENG J MED, 344(20), 2001, pp. 1527-1535
The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden
Authors: Middeldorp, S Libourel, EJ Hamulyak, K van der Meer, J Buller, HR
Citation: S. Middeldorp et al., The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden, BR J HAEM, 113(2), 2001, pp. 553-555
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism
Authors: Middeldorp, S Meinardi, JR Koopman, MMW van Pampus, ECM Hamulyak, K van der Meer, J Prins, MH Buller, HR
Citation: S. Middeldorp et al., A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism, ANN INT MED, 135(5), 2001, pp. 322-327
Hereditary and acquired thrombophilia
Authors: Bank, I Middeldorp, S Buller, HR
Citation: I. Bank et al., Hereditary and acquired thrombophilia, SEM RESP CR, 21(6), 2000, pp. 483-491
Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: Effect on different tests for INR determination
Authors: Bijsterveld, NR Middeldorp, S Berends, F Buller, HR
Citation: Nr. Bijsterveld et al., Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: Effect on different tests for INR determination, J THROMB TH, 9(3), 2000, pp. 263-269
How to decide on the optimal duration of anticoagulant therapy in carriersof the factor V Leiden mutation
Authors: Middeldorp, S Buller, HR
Citation: S. Middeldorp et Hr. Buller, How to decide on the optimal duration of anticoagulant therapy in carriersof the factor V Leiden mutation, THROMB HAEM, 84(5), 2000, pp. 740-741
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study
Authors: Middeldorp, S Meijers, JCM van den Ende, AE van Enk, A Bouma, BN Tans, G Rosing, J Prins, MH Buller, HR
Citation: S. Middeldorp et al., Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study, THROMB HAEM, 84(1), 2000, pp. 4-8
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis - A randomized cross-over study of two low-dose oral contraceptives
Authors: Meijers, JCM Middeldorp, S Tekelenburg, W van den Ende, AE Tans, G Prins, MH Rosing, J Buller, HR Bouma, BN
Citation: Jcm. Meijers et al., Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis - A randomized cross-over study of two low-dose oral contraceptives, THROMB HAEM, 84(1), 2000, pp. 9-14
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways
Authors: Tans, G Curvers, J Middeldorp, S Thomassen, MCLGD Meijers, JCM Prins, MH Bouma, BN Buller, HR Rosing, J
Citation: G. Tans et al., A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways, THROMB HAEM, 84(1), 2000, pp. 15-21
Factor XIII Va134Leu and the risk of venous thromboembolism in factor V Leiden carriers
Authors: Franco, RF Middeldorp, S Meinardi, JR van Pampus, ECM Reitsma, PH
Citation: Rf. Franco et al., Factor XIII Va134Leu and the risk of venous thromboembolism in factor V Leiden carriers, BR J HAEM, 111(1), 2000, pp. 118-121
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study
Authors: Rosing, J Middeldorp, S Curvers, J Thomassen, MCLGD Nicolaes, GAF Meijers, JCM Bouma, BN Buller, HR Prins, MH Tans, G
Citation: J. Rosing et al., Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study, LANCET, 354(9195), 1999, pp. 2036-2040
Oral contraceptives and hormonal replacement therapy cause an imbalance incoagulation and fibrinolysis which may explain the increased risk of venous thromboembolism
Authors: Levi, M Middeldorp, S Buller, HR
Citation: M. Levi et al., Oral contraceptives and hormonal replacement therapy cause an imbalance incoagulation and fibrinolysis which may explain the increased risk of venous thromboembolism, CARDIO RES, 41(1), 1999, pp. 21-24
Double-homozygosity for factor V Leiden and the prothrombin gene G20210A variant in a young patient with idiopathic venous thrombosis
Authors: Meinardi, JR Pelsma, PM Koning, H van der Meer, J Middeldorp, S Buller, HR Hamulyak, K
Citation: Jr. Meinardi et al., Double-homozygosity for factor V Leiden and the prothrombin gene G20210A variant in a young patient with idiopathic venous thrombosis, BLOOD, 94(5), 1999, pp. 1828-1829
Increased risk for fetal loss in carriers of the factor V Leiden mutation
Authors: Meinardi, JR Middeldorp, S de Kam, PJ Koopman, MMW van Pampus, ECM Hamulyak, K Prins, MH Buller, HR van der Meer, J
Citation: Jr. Meinardi et al., Increased risk for fetal loss in carriers of the factor V Leiden mutation, ANN INT MED, 130(9), 1999, pp. 736-739
Factor V : Q(506) mutation - Resistance to activated protein C (APC): Clinical implications with respect to family screening
Authors: Middeldorp, S van der Meer, J
Citation: S. Middeldorp et J. Van Der Meer, Factor V : Q(506) mutation - Resistance to activated protein C (APC): Clinical implications with respect to family screening, SEM THROMB, 24(4), 1998, pp. 363-366
Risultati: 1-15 |